Abbott Laboratories [ABT] stock is trading at $123.22, up 4.62%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABT shares have gain 10.91% over the last week, with a monthly amount glided 9.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on October 08, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $130. Previously, Piper Sandler started tracking the stock with Overweight rating on September 19, 2024, and set its price target to $131. On July 30, 2024, downgrade downgraded it’s rating to Hold. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $121 on May 30, 2024. Wolfe Research upgraded its rating to a Peer Perform. Morgan Stanley downgraded its rating to Equal-Weight for this stock on May 30, 2023, but kept the price target unchanged to $112. In a note dated April 20, 2023, Wolfe Research reiterated an Underperform rating on this stock and revised its target price from $107 to $103.
Abbott Laboratories [ABT] stock has fluctuated between $99.71 and $121.64 over the past year. Currently, Wall Street analysts expect the stock to reach $119.1 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $123.22 at the most recent close of the market. An investor can expect a potential drop of -3.34% based on the average ABT price forecast.
Analyzing the ABT fundamentals
Abbott Laboratories [NYSE:ABT] reported sales of 41.95B for the trailing twelve months, which represents a growth of 7.16%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.15 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 119.59 points at the first support level, and at 115.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 125.04, and for the 2nd resistance point, it is at 126.86.
Ratios To Look Out For
For context, Abbott Laboratories’s Current Ratio is 1.60. As well, the Quick Ratio is 1.14, while the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 5.09, the price to book ratio is 5.37 and price to earnings (TTM) ratio is 16.08.
Transactions by insiders
Recent insider trading involved Funck, Jr. Robert E., Officer, that happened on Nov 04 ’24 when 15000.0 shares were purchased. EXECUTIVE VICE PRESIDENT, ALLEN HUBERT L completed a deal on Oct 21 ’24 to sell 0.16 million shares. Meanwhile, Officer ALLEN HUBERT L bought 0.16 million shares on Oct 21 ’24.
